86 results match your criteria Parkinson-Plus Syndromes


Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes.

EJNMMI Res 2018 Dec 13;8(1):110. Epub 2018 Dec 13.

Department of Nuclear Medicine and Molecular Imaging, Division of Nuclear Medicine, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.

Background: F-FDG brain PET measures metabolic changes in neurodegenerative disorders and may discriminate between different diseases even at an early stage. The objective of this study was to classify patients with amyotrophic lateral sclerosis (ALS) and Parkinson plus syndromes (PP). To this end, different approaches were evaluated using generalized linear models and corresponding glucose metabolic brain patterns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-018-0458-5DOI Listing
December 2018

Progress in the treatment of Parkinson-Plus syndromes.

Parkinsonism Relat Disord 2018 Oct 3. Epub 2018 Oct 3.

UC San Diego Department of Neurosciences, Parkinson and Other Movement Disorder Center, La Jolla, CA, USA. Electronic address:

Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) are the four major proteinopathic neurodegenerative disorders. Currently, there are no disease modifying therapies for these disorders. However, better understanding of the etiopathogenic mechanisms of these disorders has allowed the development of novel therapeutic approaches. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183043
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.10.006DOI Listing
October 2018
7 Reads

What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective.

Parkinsonism Relat Disord 2018 Aug 30. Epub 2018 Aug 30.

Univ Lyon, Institut des Sciences Cognitives Marc Jeannerod, CNRS, UMR 5229, F-69675, Bron, France; Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson, Lyon, France; Univ Lyon, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, F-69921, Oullins, France.

The diagnosis of a parkinsonian syndrome based on clinical criteria remains sometimes difficult, especially at disease onset. Brain or heart molecular imaging techniques (SPECT or PET) can provide a major help to improve and speed up diagnosis, influencing treatment strategies. Presynaptic dopaminergic imaging using either [F]-Dopa PET or I -2β-Carbomethoxy-3β-(4-Iodophenyl)- N-(3-Fluoropropyl) Nortropane ([I]-Ioflupane)SPECT demonstrates or rules out the presence of a dopaminergic degenerative process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2018.08.016DOI Listing
August 2018
2 Reads

Jean-Martin Charcot and Parkinson's disease: Teaching and teaching materials.

Authors:
O Walusinski

Rev Neurol (Paris) 2018 Sep - Oct;174(7-8):491-505. Epub 2018 Apr 10.

Cabinet Privé, 20 rue de Chartres, 28160 Brou, France. Electronic address:

James Parkinson's 1817 seminal article was not well known in France until 1861, when Jean-Martin Charcot and his friend, Alfred Vulpian, published a detailed description in French of paralysis agitans. Their article provided clinical information to help French physicians make an accurate diagnosis by considering gait, shaking and rigidity as well as masked facies. As Charcot always had a strong desire to teach, this article describes his lessons on Parkinson's disease from 1868 to 1888, and also examines the teaching approach he used to pass on his latest findings to his students and colleagues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurol.2017.08.005DOI Listing
December 2018
6 Reads

99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes.

Nucl Med Commun 2018 Apr;39(4):312-318

Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, Punjab, India.

Introduction: Parkinson's disease (PD) and Parkinson plus syndromes (PPS) are neurodegenerative movement disorders caused by loss of dopamine in the basal ganglia. The diagnosis of both PD and PPS is complex as it is made solely on the basis of clinical features, with no established imaging modality to aid in the diagnosis. Technetium-99m-labeled tropane derivative (Tc-TRODAT-1) binds to the dopamine transporters present in the presynaptic membrane of the dopaminergic nerve terminal. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00006231-201804000-0000
Publisher Site
http://dx.doi.org/10.1097/MNM.0000000000000802DOI Listing
April 2018
18 Reads
1.371 Impact Factor

Myoclonus in the elderly: A retrospective analysis of clinical and electrophysiological characteristics of patients referred to an electrophysiology laboratory.

Parkinsonism Relat Disord 2018 Apr 26;49:22-27. Epub 2017 Dec 26.

Department of Neurology, Cerrahpaşa School of Medicine, Istanbul University, Turkey.

Background And Objective: Late-onset myoclonus in the elderly is mainly related to dementia or systemic disease. In this report, we aimed to investigate the clinical and electrophysiological features of patients with late-onset myoclonus.

Patients And Method: We retrospectively assessed the medical records of patients who were referred to our electromyography laboratory. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2017.12.026DOI Listing
April 2018
5 Reads

Clinical Profile of Cognitive Decline in Patients with Parkinson's Disease, Progressive Supranuclear Palsy, and Multiple System Atrophy.

J Neurosci Rural Pract 2017 Oct-Dec;8(4):562-568

Department of Medicine, Garg Hospital, Faridkot, Punjab, India.

Background: There are very less data on the comparison between the cognitive profile in Parkinson's disease (PD) and Parkinson's-plus groups, especially in India.

Aims: The aim of this study is to compare the cognitive profile across PD, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) groups and compare them using Mini-Mental State Examination (MMSE), frontal assessment battery (FAB), and verbal fluency tests.

Settings And Design: This was a cross-sectional study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jnrp.jnrp_154_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709878PMC
December 2017
8 Reads

CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.

J Neurol Sci 2017 Nov 28;382:91-95. Epub 2017 Sep 28.

1st Department of Neurology, National and Kapodistrian University of Athens, Eginition Hospital, 72-74 Vassilisis Sofias Avenue, Athens P.C.:11528, Greece.

Introduction: Differential diagnosis of Parkinson-plus patients (PSP, CBD, MSA) and Parkinson's disease (PD) patients is often not straightforward, particularly in atypical cases or at the initial stages of the diseases. Classic CSF biomarkers (amyloid-beta - Aβ, tau protein - τ and phosphorylated tau protein - τ) are established biomarkers in the diagnosis of Alzheimer's disease (AD). CSF a-synuclein (α-syn) has emerged as a promising biomarker in patients with Parkinsonism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2017.09.039DOI Listing
November 2017
14 Reads

Atypical parkinsonian syndromes: a general neurologist's perspective.

Eur J Neurol 2018 01 28;25(1):41-58. Epub 2017 Sep 28.

Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.

The differential diagnosis of atypical parkinsonian syndromes is challenging. These severe and often rapidly progressive neurodegenerative disorders are clinically heterogeneous and show significant phenotypic overlap. Here, clinical, imaging, neuropathological and genetic features of multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and frontotemporal lobar degeneration (FTLD) are reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ene.13412DOI Listing
January 2018
15 Reads

Can loss of the swallow tail sign help distinguish between Parkinson Disease and the Parkinson-Plus syndromes?

Clin Imaging 2017 Jul - Aug;44:66-69. Epub 2017 Apr 20.

Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. Electronic address:

Purpose: To determine if loss of the swallow tail sign (STS) can distinguish Parkinson Disease (PD) from the Parkinson-Plus syndromes.

Methods: Twenty-five patients with PD, 21 with Parkinson-Plus syndromes, and 14 control patients were included. Presence of the STS was assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinimag.2017.04.005DOI Listing
December 2017
11 Reads

Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Transl Neurodegener 2017 28;6. Epub 2017 Mar 28.

Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada.

Two centuries ago in 1817, James Parkinson provided the first medical description of Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to include the atypical parkinsonian variants (also termed, Parkinson-plus syndromes). Today, Parkinson's disease represents the second most common neurodegenerative disorder with an estimated global prevalence of over 10 million. Conversely, atypical parkinsonian syndromes encompass a group of relatively heterogeneous disorders that may share some clinical features with Parkinson's disease, but are uncommon distinct clinicopathological diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40035-017-0076-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370489PMC
March 2017
11 Reads

Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis.

J Neurol Neurosurg Psychiatry 2017 05 1;88(5):402-411. Epub 2017 Mar 1.

Hurstwood Park Neurological Centre, Brighton and Sussex University Hospitals, Brighton, UK.

Objective: To undertake a systematic review and meta-analysis of studies that investigated prognostic factors and survival in patients with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA).

Methods: Publications of at least 10 patients with a likely or confirmed diagnosis of PSP or MSA were eligible for inclusion. Methodological quality was rated using a modified version of the Quality in Prognostic Studies tool. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2016-314956DOI Listing
May 2017
3 Reads

Imagerie cérébrale dans les syndromes parkinsoniens.

Presse Med 2017 Mar 28;46(2 Pt 1):202-209. Epub 2016 Dec 28.

Université de Lyon, université Claude-Bernard Lyon I, faculté de médecine Lyon Sud Charles-Mérieux, Lyon, France; Hospices civils de Lyon, hôpital neurologique Pierre-Wertheimer, service de neurologie C, centre expert parkinson, Lyon, France; CNRS, centre de neurosciences cognitives, UMR 5229, Bron, France. Electronic address:

Role of brain imaging for Parkinsonism T brain MRI is normal in Pakinson's disease. Brain MRI is useless when clinical presentation is typical of idiopathic Parkinson's disease. Brain MRI is the exam of choice for differentiating idiopathic Parkinson's disease and atypical parkinsonism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2016.09.025DOI Listing
March 2017
13 Reads

Pain in Extrapyramidal Neurodegenerative Diseases.

Clin J Pain 2017 07;33(7):635-639

*Department of Neurology, Movement Disorder Clinic, Rabin Medical Center, Beilinson Hospital, Petach Tikva ‡Movement Disorders Unit, Tel Aviv Sourasky Medical Center †Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Objective: Pain is one of the most common nonmotor symptoms of Parkinson disease (PD) and other Parkinson plus syndromes, with a major effect on quality of life. The aims of the study were to examine the prevalence and characteristics of pain in PD and other Parkinson plus syndromes and patient use and response to pain medications.

Methods: The cohort consisted of 371 patients: 300 (81%) with PD and 71 (19%) with Parkinson plus syndromes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AJP.0000000000000437DOI Listing
July 2017
14 Reads

Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options.

Curr Treat Options Neurol 2016 Sep;18(9):42

Department of Clinical Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.

Opinion Statement: There are currently no disease-modifying treatments for progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD), and no approved pharmacological or therapeutic treatments that are effective in controlling their symptoms. The use of most pharmacological treatment options are based on experience in other disorders or from non-randomized historical controls, case series, or expert opinion. Levodopa may provide some improvement in symptoms of Parkinsonism (specifically bradykinesia and rigidity) in PSP and CBD; however, evidence is conflicting and where present, benefits are often negligible and short lived. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11940-016-0422-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985534PMC
September 2016
14 Reads

Single-photon emission tomography.

Handb Clin Neurol 2016 ;135:241-250

Division of Nuclear Medicine, University Hospital Leuven and KU Leuven, Leuven, Belgium. Electronic address:

Single-photon emission computed tomography (SPECT) is a functional nuclear imaging technique that allows visualization and quantification of different in vivo physiologic and pathologic features of brain neurobiology. It has been used for many years in diagnosis of several neurologic and psychiatric disorders. In this chapter, we discuss the current state-of-the-art of SPECT imaging of brain perfusion and dopamine transporter (DAT) imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-53485-9.00013-1DOI Listing
February 2017
6 Reads

DCTN1 p.K56R in progressive supranuclear palsy.

Parkinsonism Relat Disord 2016 07 23;28:56-61. Epub 2016 Apr 23.

Centre for Applied Neurogenetics, Djavad Mowafaghian Centre for Brain Health, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada. Electronic address:

Introduction: Mutations in dynactin DCTN1 (p150(glued)) have previously been linked to familial motor neuron disease or Perry syndrome (PS) consisting of depression, parkinsonism and hypoventilation.

Methods: We sequenced DCTN1 in 636 Caucasian patients with parkinsonism (Parkinson's disease and Parkinson-plus syndromes) and 508 healthy controls. Variants (MAF < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2016.04.025DOI Listing
July 2016
22 Reads

Autoimmune atypical parkinsonism - A group of treatable parkinsonism.

J Neurol Sci 2016 Mar 13;362:40-6. Epub 2016 Jan 13.

Department of Neurology, Amrita Institute of Medical Sciences, Ponekkara PO, Kochi 682041, Kerala, India.

Background: Immunological causes of atypical parkinsonism/Parkinson plus syndromes are rare.

Objective: To study the clinical and laboratory features and treatment outcome of autoimmune atypical parkinsonism.

Methods: Retrospective case series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2016.01.006DOI Listing
March 2016
3 Reads

Progress in unraveling the genetic etiology of Parkinson disease in a genomic era.

Trends Genet 2015 Mar 20;31(3):140-9. Epub 2015 Feb 20.

Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born Bunge, University of Antwerp, Antwerp, Belgium. Electronic address:

Parkinson disease (PD) and Parkinson-plus syndromes are genetically heterogeneous neurological diseases. Initial studies into the genetic causes of PD relied on classical molecular genetic approaches in well-documented case families. More recently, these approaches have been combined with exome sequencing and together have identified 15 causal genes. Read More

View Article

Download full-text PDF

Source
http://www.cell.com/trends/genetics/pdf/S0168-9525(15)00015-
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S016895251500015
Publisher Site
http://dx.doi.org/10.1016/j.tig.2015.01.004DOI Listing
March 2015
1 Read

Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinson's disease.

Parkinsonism Relat Disord 2015 Mar 15;21(3):205-10. Epub 2014 Dec 15.

Department of Urology, SMG-SNU Boramae Medical Center, Donggak-gu, Boramae-ro 5 Gil, 20, Seoul 156-707, Republic of Korea. Electronic address:

Introduction: To investigate differences in urodynamic parameters between two groups: Parkinson's disease (PD) and multiple system atrophy (MSA) patients.

Methods: A retrospective study was performed in patients with PD and MSA who presented to three referral centers between 2005 and 2012. Patients referred to the urology department for lower urinary tract symptoms underwent urodynamic studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2014.12.003DOI Listing
March 2015
6 Reads

Deep brain stimulation in multiple system atrophy mimicking idiopathic Parkinson's disease.

Case Rep Neurol 2014 Sep 23;6(3):232-7. Epub 2014 Oct 23.

Department of Neurosurgery, John Radcliffe Hospital, Oxford, UK.

Deep brain stimulation (DBS) is approved for idiopathic Parkinson's disease (IPD) but has a poor evidence base in Parkinson-plus syndromes such as multiple system atrophy (MSA). We describe the clinical and neuropathological findings in a man who was initially diagnosed with IPD, in whom DBS was unsuccessful, and in whom MSA was unexpectedly diagnosed at a subsequent autopsy. This case report highlights that DBS is often unsuccessful in MSA and also demonstrates that MSA can masquerade as IPD, which may explain treatment failure in a small group of patients apparently suffering from Parkinson's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000368571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250004PMC
September 2014
13 Reads

Trial of Zolpidem, Eszopiclone, and Other GABA Agonists in a Patient with Progressive Supranuclear Palsy.

Case Rep Med 2014 16;2014:107064. Epub 2014 Sep 16.

Department of Internal Medicine, Stanford University Medical Center, 300 Pasteur Drive, Palo Alto, CA 94305, USA ; Palo Alto Medical Foundation, 795 El Camino Real, Palo Alto, CA 94301, USA.

Progressive supranuclear palsy (PSP) is a progressive, debilitating neurodegenerative disease of the Parkinson-plus family of syndromes. Unfortunately, there are no pharmacologic treatments for this condition, as most sufferers of the classic variant respond poorly to Parkinson medications such as levodopa. Zolpidem, a gamma aminobutyric acid (GABA) agonist specific to the α-1 receptor subtype, has been reported to show improvements in symptoms of PSP patients, including motor dysfunction, dysarthria, and ocular disturbances. Read More

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/crim/2014/107064/
Publisher Site
http://dx.doi.org/10.1155/2014/107064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209775PMC
November 2014
3 Reads

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy.

Neuropsychiatr Dis Treat 2014 5;10:1003-9. Epub 2014 Jun 5.

IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson's disease (PD). RTG patch has many potential advantages due to the immediacy of onset of the therapeutic effect. Of note, intestinal absorption is not necessary and drug delivery is constant, thereby avoiding drug peaks and helping patient compliance. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/rotigotine-is-safe-and-efficacious-
Publisher Site
http://dx.doi.org/10.2147/NDT.S64015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051815PMC
June 2014
17 Reads

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

Lancet Neurol 2014 Jul 27;13(7):676-85. Epub 2014 May 27.

Celerion, Lincoln, NE, USA.

Background: In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation. Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP. We assessed the safety and efficacy of davunetide in patients with PSP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(14)70088-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129545PMC
July 2014
40 Reads

The value of novel MRI techniques in Parkinson-plus syndromes: diffusion tensor imaging and anatomical connectivity studies.

Rev Neurol (Paris) 2014 Apr 20;170(4):266-76. Epub 2014 Mar 20.

Service de neurologie et pathologie du mouvement, hôpital Salengro, CHRU de Lille, EA 1046, département de pharmacologie médicale, université Lille Nord de France, 1, place de Verdun, 59045 Lille cedex, France.

Conventional MRI is a well-described, highly useful tool for the differential diagnosis of degenerative parkinsonian syndromes. Nevertheless, the observed abnormalities may only appear in late-stage disease. Diffusion tensor imaging (DTI) can identify microstructural changes in brain tissue integrity and connectivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurol.2013.10.013DOI Listing
April 2014
11 Reads

The applause sign in Parkinson's disease patients is related to dysexecutive syndrome.

J Clin Neurosci 2013 Dec 20;20(12):1734-6. Epub 2013 Aug 20.

Department of Neurology, Osijek University Hospital Center, J. Huttlera 4, HR-31000 Osijek, Croatia. Electronic address:

Recent publications report that a positive applause sign is not only present in patients with neurodegenerative diseases where the subcortical structures are affected but also in patients with cortical dementia. The nature of this sign remains unknown. This study aimed to determine the frequency of the applause sign and its correlation with cognitive impairment in patients with idiopathic Parkinson's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2013.02.024DOI Listing
December 2013
5 Reads

Surgical management of airway dysfunction in Parkinson's disease compared with Parkinson-plus syndromes.

Ann Otol Rhinol Laryngol 2013 May;122(5):294-8

New York Center for Voice and Swallowing Disorders, St Luke's Roosevelt Medical Center, New York, NY 10019, USA.

Objectives: We sought to compare the laryngeal symptoms of Parkinson's disease (PD) with those of multiple system atrophy (MSA), a Parkinson-plus syndrome; to review the differences in surgical management of upper airway dysfunction between patients with PD and those with MSA; and to present a treatment algorithm for management of upper airway disorders in patients with PD and MSA.

Methods: We analyzed the airway manifestations of each disease, including clinical and physiological test results and management outcomes, in a case series of 30 patients (24 with PD and 6 with MSA).

Results: Vocal fold atrophy causing bowing with a midfold glottic gap was common in patients with PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/000348941312200502DOI Listing
May 2013
7 Reads

Levodopa Responsiveness in Adult-onset Lower Limb Dystonia is Associated with the Development of Parkinson's Disease.

Tremor Other Hyperkinet Mov (N Y) 2013 18;3. Epub 2013 Apr 18.

Mayo Clinic, Rochester, Minnesota, United States of America.

Background: Adult-onset primary lower limb dystonia (AOPLLD) has been reported as an early sign of Parkinson's disease (PD) or Parkinson-plus syndrome in case series. No prior systematic analysis has assessed clinical clues predicting later development of PD or Parkinson-plus syndrome.

Methods: We identified patients with AOPLLD from medical records. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629864PMC
http://dx.doi.org/10.7916/D8VD6X5MDOI Listing
April 2013
5 Reads

Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy.

Mov Disord 2013 Apr 21;28(4):504-9. Epub 2013 Feb 21.

Department of Neurology, Philipps Universität, Marburg, Germany.

Autopsy is the diagnostic gold standard for progressive supranuclear palsy (PSP). The National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of "probable" PSP are thought to possess high specificity and low sensitivity. The NINDS-SPSP criteria for "possible" PSP are considered to increase sensitivity at the expense of specificity. Read More

View Article

Download full-text PDF

Source
http://www.expy.cz/userfiles/file/PSP%20guidelines.pdf
Web Search
http://doi.wiley.com/10.1002/mds.25327
Publisher Site
http://dx.doi.org/10.1002/mds.25327DOI Listing
April 2013
9 Reads

[Vascular or "lower body Parkinsonism": rise and fall of a diagnosis].

Authors:
Imre Szirmai

Ideggyogy Sz 2011 Nov;64(11-12):385-93

Semmelweis Egyetem, Neurológiai Klinika, Budapest.

Unlabelled: The "arteriosclerotic parkinsonism", which is called vascular parkinsonism (VP), was first described by Critchley'. The broad based slow gait, reduced stride lenght, start hesitation, freezing and paratonia was mentioned as "lower body parkinsonism" (LBP) which can be associated by slow speech, dysexecutive syndrome, and hand tremor of predominantly postural character. In VP the DAT-scan proved normal dopamine content of the striatum in contrast with Parkinson's disease (PD). Read More

View Article

Download full-text PDF

Source
November 2011
10 Reads

Serum iron, vitamin B12 and folic acid levels in Parkinson's disease.

Neurochem Res 2012 Jul 26;37(7):1436-41. Epub 2012 Feb 26.

Ankara Numune Egitim ve Arastirma Hastanesi, Noroloji Klinigi, Talatpasa, Bulvari, Samanpazari, Ankara, Turkey.

We aimed to investigate possible associations between systemic iron metabolism deficiency and Parkinson's disease, and also to research any possible correlations between stage of the disease and vitamin B12 and folic acid levels. 33 male and 27 female patients diagnosed with idiopathic Parkinson's disease and 22 male and 20 female age- and sex-matched controls were enrolled in the study. Having the diagnosis of secondary Parkinsonism or Parkinson plus syndromes, and for the females, not being in the menopausal stage were considered as exclusion criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11064-012-0729-xDOI Listing
July 2012
3 Reads

Treatment options for tauopathies.

Curr Treat Options Neurol 2012 Apr;14(2):126-36

Department of Psychiatry, J.W. Goethe-University, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt, Germany,

Opinion Statement: To date, there are no approved and established pharmacologic treatment options for tauopathies, a very heterogenous group of neuropsychiatric diseases often leading to dementia and clinically diagnosed as atypical Parkinson syndromes. Among these so-called Parkinson plus syndromes are progressive supranuclear palsy (PSP), also referred to as Steele-Richardson-Olszewski syndrome; frontotemporal dementia (FTD); and corticobasal degeneration (CBD). Available treatment strategies are based mainly on small clinical trials, miscellaneous case reports, or small case-controlled studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11940-012-0168-7DOI Listing
April 2012
12 Reads

Neuroleptic malignant syndrome in a patient with corticobasal degeneration.

J Mov Disord 2011 Oct 30;4(2):73-4. Epub 2011 Oct 30.

Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Parkinson's disease is a principal underlying disease of neuroleptic malignant syndrome (NMS) occurring in parkinsonian disorders, but NMS may occur in patients with progressive supranuclear palsy and multiple system atrophy. We report first patient with corticobasal degeneration (CBD) who developed NMS after abrupt reduction of antiparkinsonian medication and concurrent infection. It should be kept in mind that the prevention of infectious illness, which is common complication in parkinson-plus syndrome, is important, and dose reduction or withdrawal of anti-parkinsonian medications should be carefully performed even in the patients with CBD who are expected to be unresponsive to levodopa treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14802/jmd.11015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027684PMC
October 2011
2 Reads

[Neurology of laughter and humour: pathological laughing and crying].

Authors:
Manuel Arias

Rev Neurol 2011 Oct;53(7):415-21

Servicio de Neurología, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, España.

Introduction: Laughter, which is usually a healthy biological phenomenon, may be also a symptom of several severe brain pathologies.

Aim: To review the neurobiological bases of laughter and humour, as well as those of pathological laughing and crying syndrome.

Development: At the mesencephalic-pontine junction there is a central coordinator of the nuclei that innervate the muscles involved in laughter (facial expression, respiratory and phonatory). Read More

View Article

Download full-text PDF

Source
October 2011
2 Reads

Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale.

PLoS One 2011 4;6(8):e22293. Epub 2011 Aug 4.

Département de Pharmacologie Clinique, Hôpital de la Pitié-Salpêtrière, APHP, UPMC Pharmacologie, Paris 6, UMR 7211, Paris, France.

Background: The Natural History and Neuroprotection in Parkinson Plus Syndromes (NNIPPS) study was a large phase III randomized placebo-controlled trial of riluzole in Progressive Supranuclear Palsy (PSP, n = 362) and Multiple System Atrophy (MSA, n = 398). To assess disease severity and progression, we constructed and validated a new clinical rating scale as an ancillary study.

Methods And Findings: Patients were assessed at entry and 6-montly for up to 3 years. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0022293PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150329PMC
December 2011
16 Reads

Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.

Brain 2010 Aug 24;133(Pt 8):2382-93. Epub 2010 Jun 24.

King's College London, MRC Centre of Neurodegeneration Research, Institute of Psychiatry, Department of Psychology, PO77, London SE5 8AF, UK.

This article reports the severity and profile of neuropsychological impairment on a prevalent cohort of patients with a clinical diagnosis of either multiple system atrophy (n=372) or progressive supranuclear palsy (n=311) from the Neuroprotection and Natural History in Parkinson Plus Syndromes cohort. The Dementia Rating Scale and Frontal Assessment Battery were used to assess global cognition and executive dysfunction. For the Dementia Rating Scale impairment was observed in approximately 57% of the progressive supranuclear palsy group and 20% of the multiple system atrophy group. Read More

View Article

Download full-text PDF

Source
http://brain.oxfordjournals.org/content/brain/133/8/2382.ful
Web Search
http://www.brain.oxfordjournals.org/cgi/doi/10.1093/brain/aw
Publisher Site
http://dx.doi.org/10.1093/brain/awq158DOI Listing
August 2010
2 Reads

Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.

Hum Mutat 2010 Jul;31(7):763-80

Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerpen, Belgium.

To date, molecular genetic analyses have identified over 500 distinct DNA variants in five disease genes associated with familial Parkinson disease; alpha-synuclein (SNCA), parkin (PARK2), PTEN-induced putative kinase 1 (PINK1), DJ-1 (PARK7), and Leucine-rich repeat kinase 2 (LRRK2). These genetic variants include approximately 82% simple mutations and approximately 18% copy number variations. Some mutation subtypes are likely underestimated because only few studies reported extensive mutation analyses of all five genes, by both exonic sequencing and dosage analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.21277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056147PMC
July 2010
5 Reads

Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy.

PLoS One 2009 Sep 22;4(9):e7114. Epub 2009 Sep 22.

MRC Centre for Neurodegeneration Research, King's College London, Department of Clinical Neuroscience, Institute of Psychiatry, and NIHR Biomedical Research Centre, London, United Kingdom.

Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by parkinsonism, cerebellar ataxia and autonomic dysfunction. Pathogenic mechanisms remain obscure but the neuropathological hallmark is the presence of alpha-synuclein-immunoreactive glial cytoplasmic inclusions. Genetic variants of the alpha-synuclein gene, SNCA, are thus strong candidates for genetic association with MSA. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007114PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743996PMC
September 2009
8 Reads

In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia.

Behav Brain Res 2009 Dec 10;204(1):1-31. Epub 2009 Jun 10.

Clinic of Nuclear Medicine, University Hospital Düsseldorf, Heinrich-Heine University, Moorenstr. 5, 40225 Düsseldorf, Germany.

This review gives an overview of those in vivo imaging studies on synaptic neurotransmission, which so far have been performed on patients with movement disorders and/or dementia. Thereby, the focus is on disease-related deficiencies within the functional entity of the dopaminergic, serotonergic, cholinergic, glutamatergic, GABAergic or opioid synapse. In vivo investigations have yielded highly consistent results on the dysfunction of synaptic constituents in the majority of diseases covered by this overview. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbr.2009.06.008DOI Listing
December 2009
3 Reads

[Differential diagnosis of Parkinson's syndromes--an overview].

Dtsch Med Wochenschr 2009 Apr 15;134(17):892-6. Epub 2009 Apr 15.

Abteilung Neurologie, Universitätsmedizin Göttingen.

With regard to aging of the general population non-neurologists are more frequently confronted with patients presenting with parkinsonian symptoms. The central task concerning treatment and prognosis in such cases is to differentiate idiopathic Parkinson's disease from secondary Parkinson syndromes and so called Parkinson-Plus-Syndromes. Besides clinical presentation neuroimaging techniques have been established in recent years, which can help with correct classification in early disease stages and difficult cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0029-1220245DOI Listing
April 2009
4 Reads

Transcranial sonography in movement disorders.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008 Dec;152(2):251-8

Department of Neurology, University Hospital, Ostrava, Czech Republic.

Background: Transcranial sonography (TCS) in the B-mode has the ability to image, infratentorial and supratentorial brain structures. For this reason, it has potential use in the diagnosis and differential diagnosis of various intracranial pathologies.

Methods And Results: The authors reviewed the contribution of TCS to the differentiation of a number of neurodegenerative diseases: in parkinsonian syndromes, TCS can evaluate echogenicity changes in specific structures such as the hyperechogenic area of the substantia nigra (SN) in Parkinson's disease and the hyperechogenic caudate nucleus in Huntington's disease as well as the hyperechogenic lentiform nucleus (LN) in dystonia and Wilson's disease. Read More

View Article

Download full-text PDF

Source
December 2008
9 Reads

Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population.

J Neurol Sci 2009 Apr 26;279(1-2):39-42. Epub 2009 Jan 26.

Division of Cell Biology and Physiology, Laboratory of Clinical & Experimental Neuroscience, Indian Institute of Chemical Biology (CSIR), Kolkata, West Bengal, India.

The observation of decline in mitochondrial electron transport chain function, specifically at complex I, in patients with Parkinson's disease (PD) has been reported by several groups. This study investigates whether a defect of mitochondrial function is present in the platelets of PD patients from an Indian population. We found that the NADH dehydrogenase activity in the platelets of PD patients is lower than that in healthy age- and gender-matched controls, while the succinate dehydrogenase activity was similar in both groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2008.12.021DOI Listing
April 2009
4 Reads

Automated computer differential classification in Parkinsonian Syndromes via pattern analysis on MRI.

Acad Radiol 2009 Jan;16(1):61-70

Department of Radiology, Robert Giffard Research Center, Laval University, Quebec, PQ, Canada.

Rationale And Objectives: Reported error rates for initial clinical diagnosis of idiopathic Parkinson's disease (IPD) against other Parkinson Plus Syndromes (PPS) can reach up to 35%. Reducing this initial error rate is an important research goal. We evaluated the ability of an automated technique, based on structural, cross-sectional T1-weighted (T1w) magnetic resonance imaging, to perform differential classification of IPD patients versus those with either progressive supranuclear palsy (PSP) or multiple systems atrophy (MSA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2008.05.024DOI Listing
January 2009
2 Reads

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Brain 2009 Jan 23;132(Pt 1):156-71. Epub 2008 Nov 23.

Département de Pharmacologie Clinique, Hôpital de la Pitié-Salpétrière, Assistance Publique Hôpitaux de Paris & UPMC University Paris 06, UMR 7087, Paris, France.

Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIPPS: Neuroprotection and Natural History in Parkinson Plus Syndromes). We analysed the accuracy of our clinical diagnostic criteria, and studied prognostic factors for survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awn291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2638696PMC
January 2009
13 Reads

The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations.

Arch Neurol 2008 Oct;65(10):1353-7

Section on Molecular Neurogenetics, National Human Genome Research Institute, National Institutes of Health, 35 Convent Dr, MSC 3708, Bldg 35, Room 1A213, Bethesda, MD 20892-3708, USA.

Background: Mutations in the glucocerebrosidase gene (GBA) result in Gaucher disease and can be associated with a phenotype characterized by adult-onset progressive neurologic deterioration and parkinsonism.

Objective: To define the clinical and neurologic spectrum of parkinsonian manifestations associated with GBA mutations. Design, Setting, and Patients A prospective case series of 10 patients (7 men and 3 women) with parkinsonism and GBA mutations evaluated at the National Institutes of Health Clinical Center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archneur.65.10.1353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629407PMC
October 2008
3 Reads

Antineuronal antibodies in Parkinson's disease.

Mov Disord 2008 May;23(7):958-963

Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, United Kingdom.

Antineuronal antibodies (ANAs) have been implicated in the pathophysiology of postinfectious movement disorders, such as Sydenham's chorea. However, their relevance in other movement disorders--in the absence of infectious triggers--remains much disputed. We sought to assess the frequency of ANAs in idiopathic Parkinson's disease (IPD) and to explore whether a specific phenotype is associated with the presence of ANAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.21929DOI Listing
May 2008
3 Reads

Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease--a rCBF scintigraphy study.

Acta Neurol Scand 2007 Dec 10;116(6):347-54. Epub 2007 Oct 10.

Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Goteborg University, Mölndal, Sweden.

Objectives: The aim of the study was to visualize cortical function in Parkinson's patients with various degrees of cognitive impairment.

Materials And Methods: Thirty-seven patients with Parkinson's disease and three with Parkinson plus syndromes underwent cognitive assessment and rCBF using (99m)TC-HMPAO-SPECT.

Results: Almost no regional reductions in cerebral blood flow were seen in patients without cognitive impairment (n = 16). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0404.2007.00887.xDOI Listing
December 2007
6 Reads

Prevalence of essential tremor in patients with Parkinson's disease vs. Parkinson-plus syndromes.

Mov Disord 2007 Jul;22(10):1402-7

Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA.

Clinical literature suggests an association between essential tremor (ET) and Parkinson's disease (PD), and recent pathological studies describe Lewy bodies in some ET patients. If some ET were an expression of Lewy body disease, one could hypothesize that ET patients who develop parkinsonism would more likely develop PD (a Lewy body disease) than non-Lewy body forms of parkinsonism. The objective was to compare the proportions of patients with PD vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.21383DOI Listing
July 2007
4 Reads

Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders.

Nucl Med Rev Cent East Eur 2006 ;9(2):147-53

12nd Laboratory of Nuclear Medicine--AHEPA University Hospital, Thessaloniki, Greece.

In this article the role of molecular imaging with SPECT and PET in patients with movement disorders is reviewed. It is mentioned that SPECT and PET imaging with cocaine analogues ((123)I-beta-CIT,(123)I-FP-CIT, (18)F-DOPA), radioligands labeling the presynaptic dopamine transporters, is of value for the differentiation of patients with PD or Parkinson-plus syndromes with individuals with essential tremor. In addition the clinical impact of this procedure, the role of molecular imaging in the preclinical diagnosis and in the follow-up of patients with PD, as well as, in the differential diagnosis between Alzheimer's disease and Lewy-body dementia, is evaluated. Read More

View Article

Download full-text PDF

Source
June 2007
2 Reads